MetaCap

Alterity Therapeutics (ATHE) vs NextCure (NXTC)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

NextCure (NXTC) has outperformed Alterity Therapeutics (ATHE) over the past year, losing 38.6% versus a loss of 56.7%. Over five years, ATHE leads with a -85.4% price change compared with -91.1% for NXTC. NextCure is the larger company by market cap ($29.5 million vs $29.0 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ATHE-56.70%NXTC-38.63%
+75%-8%-92%
Nov 21, 20251 yearNov 20, 2026
ATHE-85.93%NXTC-90.73%
+12%-46%-103%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ATHE versus NXTC key metrics
MetricATHENXTC
Share price$1.52$6.45
Market cap$29.02M$29.53M
1-day change-8.16%-4.87%
YTD return-50.65%-54.55%
1-year return-56.70%-38.63%
5-year return-85.38%-91.07%
EPS (TTM)$-0.90$-6.78
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)—$-55.84M
52-week high$5.89$15.74
52-week low$1.52$1.55
Distance from 52-week high-74.19%-59.02%
Analyst consensusnonenone
Avg. price target upside+771.71%+210.08%
Average volume89.63K79.46K
Shares outstanding19.09M4.58M
Employees1140
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • NXTC has outperformed ATHE by 18.1 percentage points over the past year.

About Alterity Therapeutics

ATHE stock →

Alterity Therapeutics Limited is engages in research and development of Parkinsonian and neurodegenerative disorders, including Multiple System Atrophy (MSA) and Parkinson's disease. The company's lead drug candidate is ATH434, a small molecule drug candidate that has completed Phase II clinical trial for the treatment of Parkinson's disease.

Health Care · Biotechnology: Pharmaceutical Preparations · 11 employees

About NextCure

NXTC stock →

NextCure, Inc., a clinical-stage biopharmaceutical company, engages in advancing medicines to treat cancer. The company's product candidate is the LNCB74, a B7-H4 targeted ADC to kill tumors.

Health Care · Biotechnology: Pharmaceutical Preparations · 40 employees

ATHE vs NXTC FAQ

Which is bigger, Alterity Therapeutics or NextCure?

NextCure (NXTC) is larger, with a market capitalization of $29.53M compared with $29.02M for Alterity Therapeutics (ATHE).

Which stock has performed better over the past year, ATHE or NXTC?

NXTC returned -38.63% over the past 12 months, compared with -56.70% for ATHE (price return, excluding dividends). Past performance does not predict future results.

Are Alterity Therapeutics and NextCure in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons